These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance. Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668 [TBL] [Abstract][Full Text] [Related]
9. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117 [TBL] [Abstract][Full Text] [Related]
10. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006 [TBL] [Abstract][Full Text] [Related]
11. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. Ong CW; Maxwell P; Alvi MA; McQuaid S; Waugh D; Mills I; Salto-Tellez M J Pathol Clin Res; 2018 Apr; 4(2):103-113. PubMed ID: 29665325 [TBL] [Abstract][Full Text] [Related]
12. Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis. Wardale L; Cardenas R; Gnanapragasam VJ; Cooper CS; Clark J; Brewer DS Curr Oncol; 2022 Dec; 30(1):157-170. PubMed ID: 36661662 [TBL] [Abstract][Full Text] [Related]
13. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of PCS and PAM50 prostate cancer classification schemes. Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653 [TBL] [Abstract][Full Text] [Related]
16. Reference-free transcriptome signatures for prostate cancer prognosis. Nguyen HTN; Xue H; Firlej V; Ponty Y; Gallopin M; Gautheret D BMC Cancer; 2021 Apr; 21(1):394. PubMed ID: 33845808 [TBL] [Abstract][Full Text] [Related]
17. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337 [TBL] [Abstract][Full Text] [Related]
18. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer. Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723 [TBL] [Abstract][Full Text] [Related]
19. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. Chen JL; Li J; Stadler WM; Lussier YA J Am Med Inform Assoc; 2011; 18(4):392-402. PubMed ID: 21672909 [TBL] [Abstract][Full Text] [Related]
20. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account. Chen X; Xu S; McClelland M; Rahmatpanah F; Sawyers A; Jia Z; Mercola D PLoS One; 2012; 7(9):e45178. PubMed ID: 23028830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]